The comprehensive hemostasis and thrombosis program provides state-of-the-art diagnostic and therapeutic services for children with inherited and acquired disorders of the blood coagulation system.
Weill Cornell Medicine's Hemophilia Treatment Center (HTC) is one of the oldest in the country and one of the first designated Hemophilia Treatment Centers, established in the 1970s by Margaret W. Hilgartner, MD. Our team provides state-of-the-art, multidisciplinary care for children and adolescents with bleeding disorders such as hemophilia, von Willebrand disease, and other rare coagulation factor deficiencies, as well as those with blood clots, including monitoring of children on anti-coagulation therapy.
Our goal is to normalize a child's life as much as possible through home infusions for prophylaxis, counseling about activities and avoiding trauma, and preventive care from a team that includes physical therapists, orthopedic surgeons, and genetic counselors, in addition to our pediatric physicians and nurses.
The HTC also conducts clinical trials of new factor replacement products and other new treatment.
The Pediatric Thrombosis program treats and manages children who have had blood clots, following them closely as long as they are on treatment.
Our team participates in clinical trials which study the new agents before they are approved, collecting important data on safety and efficacy.
We have created a registry for any child with a blood clot, coupling clinical information with data on potential risk factors from procedures, immobility, genetics, lifestyle, medications, and activity to predict a child’s risk of further complications. The goal is to identify patients who may benefit from preventive anti-coagulation treatment.
For more information about the registry, please contact us at (212) 746-3400.